Sabby Management LLC Acquires Shares of 190,658 Biodexa Pharmaceuticals PLC Unsponsored ADR $BDRX

Sabby Management LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th largest position. Sabby Management LLC owned about 0.28% of Biodexa Pharmaceuticals at the end of the most recent quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BDRX. Wall Street Zen lowered shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 30th. Weiss Ratings downgraded shares of Biodexa Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, June 3rd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Biodexa Pharmaceuticals currently has an average rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

Shares of Biodexa Pharmaceuticals stock opened at $2.98 on Wednesday. Biodexa Pharmaceuticals PLC Unsponsored ADR has a 1 year low of $2.86 and a 1 year high of $66.50. The stock has a 50-day moving average price of $3.46 and a 200 day moving average price of $8.42.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last issued its earnings results on Friday, March 27th. The company reported $3.52 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $3.53.

Biodexa Pharmaceuticals Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.